Raab & Moskowitz Asset Management LLC Sells 679 Shares of Eli Lilly and Company $LLY

Raab & Moskowitz Asset Management LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 26.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,850 shares of the company’s stock after selling 679 shares during the quarter. Raab & Moskowitz Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,702,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Tanager Wealth Management LLP lifted its position in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after purchasing an additional 10 shares in the last quarter. Wealthspan Partners LLC grew its stake in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after purchasing an additional 10 shares in the last quarter. G&S Capital LLC raised its position in Eli Lilly and Company by 2.0% in the 4th quarter. G&S Capital LLC now owns 501 shares of the company’s stock worth $538,000 after purchasing an additional 10 shares during the last quarter. Finally, Serenus Wealth Advisors LLC raised its position in Eli Lilly and Company by 2.3% in the 4th quarter. Serenus Wealth Advisors LLC now owns 439 shares of the company’s stock worth $472,000 after purchasing an additional 10 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly continues to pull ahead of Novo Nordisk in the rapidly expanding obesity-treatment market, with significantly stronger recent revenue growth and a more favorable outlook. Lilly’s latest reported quarter included 55.5% year-over-year revenue growth, while Novo Nordisk expects an adjusted sales decline. Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed.
• Positive Sentiment: The company is investing another $750 million with Resilience to expand U.S. manufacturing capacity for diabetes and obesity medicines. The project is expected to add at least 400 jobs and supports Lilly’s ability to meet continued demand. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
• Positive Sentiment: Completion of a late-stage retatrutide trial provides a potential future catalyst in diabetes, obesity and related cardiovascular indications. Lilly has also begun an early-stage study of eloralintide, adding another candidate to its weight-loss pipeline. Lilly’s Retatrutide Trial Completion Signals Next Wave in Diabetes and Obesity Drugs
• Neutral Sentiment: Analysts are focused on key operating metrics for Lilly’s second-quarter results, including demand, prescription trends and guidance. The company’s prior earnings report substantially exceeded estimates, raising expectations for the upcoming release. Lilly Q2 Earnings on the Horizon
• Negative Sentiment: Weight-loss drug stocks came under pressure as investors digested clinical-trial news and positioned ahead of earnings. Technical selling intensified after Lilly fell below a closely watched support level, despite its stronger long-term fundamentals. Weight Loss Drug Stocks Slump

Analyst Ratings Changes

A number of research analysts have commented on the company. Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Bank of America raised their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Finally, Barclays lifted their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company Stock Down 0.5%

Eli Lilly and Company stock opened at $1,149.28 on Friday. The firm has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 40.83, a PEG ratio of 1.43 and a beta of 0.51. The company’s 50 day simple moving average is $1,152.66 and its 200 day simple moving average is $1,044.16. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.34 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 34.91 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.